SciClone Pharmaceuticals (Holdings) Limited

SEHK:6600 Stock Report

Market Cap: HK$11.4b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

SciClone Pharmaceuticals (Holdings) Management

Management criteria checks 2/4

SciClone Pharmaceuticals (Holdings)'s CEO is Hong Zhao, appointed in Jun 2020, has a tenure of 4.08 years. total yearly compensation is CN¥25.33M, comprised of 32.6% salary and 67.4% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth HK$20.59M. The average tenure of the management team and the board of directors is 2.1 years and 3.4 years respectively.

Key information

Hong Zhao

Chief executive officer

CN¥25.3m

Total compensation

CEO salary percentage32.6%
CEO tenure4.1yrs
CEO ownership0.2%
Management average tenure2.1yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31
SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02
Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04
We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02
An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

CEO Compensation Analysis

How has Hong Zhao's remuneration changed compared to SciClone Pharmaceuticals (Holdings)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023CN¥25mCN¥8m

CN¥1b

Sep 30 2023n/an/a

CN¥1b

Jun 30 2023n/an/a

CN¥953m

Mar 31 2023n/an/a

CN¥904m

Dec 31 2022CN¥17mCN¥8m

CN¥855m

Sep 30 2022n/an/a

CN¥844m

Jun 30 2022n/an/a

CN¥833m

Mar 31 2022n/an/a

CN¥878m

Dec 31 2021CN¥26mCN¥7m

CN¥923m

Sep 30 2021n/an/a

CN¥837m

Jun 30 2021n/an/a

CN¥779m

Mar 31 2021n/an/a

CN¥766m

Dec 31 2020CN¥29mCN¥7m

CN¥754m

Sep 30 2020n/an/a

CN¥817m

Dec 31 2019CN¥15mCN¥6m

CN¥615m

Compensation vs Market: Hong's total compensation ($USD3.48M) is above average for companies of similar size in the Hong Kong market ($USD513.78K).

Compensation vs Earnings: Hong's compensation has increased by more than 20% in the past year.

CEO

Hong Zhao (61 yo)

4.1yrs

Tenure

CN¥25,334,000

Compensation

Mr. Hong Zhao has been President and Chief Executive Officer at SciClone Pharmaceuticals (Holdings) Limited since June 24, 2020 and also serves as its Executive Director since June 24, 2020. Mr. Zhao serve...

Leadership Team

NamePositionTenureCompensationOwnership
Hong Zhao
CEO, President & Executive Director4.1yrsCN¥25.33m0.18%
HK$ 20.6m
Rongrong Pan
Company Secretaryless than a yearCN¥6.92m0.026%
HK$ 3.0m
Chihwen Shao
VP & Head of Technical Operations and Pharmacovigilance2.5yrsno datano data
Min Jia
VP & Head of Immunization Business Unitno datano datano data
Mingxiang Wu
VP and Head of Market Access & Commercial Operation (MACO) Departmentno datano datano data
Lianzong Wu
VP and Head of Registration & Pharmaceutical Affairs Departmentno datano datano data
Li Mao
VP, GM of Research and Development & Chief Medical Officer2.1yrsno datano data
Min Wu
VP & Chief Business Development Officerless than a yearno datano data

2.1yrs

Average Tenure

55yo

Average Age

Experienced Management: 6600's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hong Zhao
CEO, President & Executive Director4.1yrsCN¥25.33m0.18%
HK$ 20.6m
Rongrong Pan
Company Secretary1.2yrsCN¥6.92m0.026%
HK$ 3.0m
Daniel Vasella
Non-Executive Director3.9yrsCN¥658.00kno data
Guoen Liu
Independent Non-Executive Director3.4yrsCN¥658.00kno data
Zhenfu Li
Non-Executive Chairman4.1yrsno datano data
Wendy Hayes
Independent Non-Executive Director3.4yrsCN¥658.00kno data
Yi-Hsien Lin
Non-Executive Director3.4yrsno datano data
Ping Chen
Independent Non-Executive Director3.4yrsCN¥658.00kno data
Yushao Gu
Independent Non-Executive Director3.4yrsCN¥658.00kno data

3.4yrs

Average Tenure

61yo

Average Age

Experienced Board: 6600's board of directors are considered experienced (3.4 years average tenure).